Core Viewpoint - Gilead Sciences-B (01672) shows a recovery of nearly 3%, with a current increase of 2.01% to HKD 13.2, and a trading volume of HKD 31.84 million [1] Group 1: Clinical Trial Results - On December 15, Gilead Sciences-B announced positive topline results from a randomized, double-blind, placebo-controlled Phase I clinical trial (NCT07024602) conducted in the United States [1] - The trial involved 46 healthy subjects who received single doses of ASC50 at varying strengths (10 mg, 30 mg, 100 mg, 200 mg, 400 mg, or 600 mg) or matching placebo [1] - The study aimed to evaluate the safety, tolerability, pharmacokinetics, and targeted binding characteristics of interleukin-17A (IL-17A) in peripheral circulation [1] Group 2: Product Information - ASC50 is an orally administered small molecule IL-17 targeted inhibitor developed by Gilead, which has been validated biologically and holds significant commercial value for various autoimmune and inflammatory diseases, including psoriasis [1] - ASC50 is classified as a new chemical entity (NCE) and is protected by patents in the U.S. and globally, with patent protection lasting until 2043 (excluding potential patent extensions) [1]

Core Viewpoint - The announcement from Gilead Sciences-B (01672) regarding positive results from the ASC50 clinical trial has led to a nearly 3% increase in stock price, reflecting investor optimism about the drug's potential in treating autoimmune diseases [1] Group 1: Clinical Trial Results - Gilead announced positive topline results from a Phase I clinical trial (NCT07024602) for ASC50, which was a randomized, double-blind, placebo-controlled study conducted in the United States [1] - The trial involved 46 healthy participants who received varying doses of ASC50 (10 mg, 30 mg, 100 mg, 200 mg, 400 mg, or 600 mg) or a matching placebo [1] - The study aimed to evaluate the safety, tolerability, pharmacokinetics, and targeted binding characteristics of ASC50 to interleukin-17A (IL-17A) [1] Group 2: Drug Information - ASC50 is an orally administered small molecule IL-17 targeted inhibitor developed by Gilead, which has shown biological validation and commercial potential in treating psoriasis and other autoimmune and inflammatory diseases [1] - ASC50 is classified as a new chemical entity (NCE) and is protected by patents in the U.S. and globally, with patent protection lasting until 2043, excluding potential extensions [1]